CLINICAL EVALUATION OF THRIPHALA CHOORNA IN NON- ALCOHOLIC FATTY LIVER DISEASE

Effect of processed Thriphala churna in Non- alcoholic Seatohepatitis

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020021

Enrollment

100

Registered

2019-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K740- Hepatic fibrosis

Interventions

Intervention1: Processed Thriphala choorna: Therapeutic Purgation for one day two processed Thriphala tablets twice a day for six months. will advice for Dietary regimen and excecise Control Interven

Eligibility

Inclusion criteria

Inclusion criteria: Consecutive patients of the age group 20 to 65 years who are diagnosed as Non alcoholic fatty liver disease with significant Fibrosis.

Exclusion criteria

Exclusion criteria: Major systemic illness, Hepatitis, unwilling patients

Design outcomes

Primary

Measure	Time frame
, CBC, LFT,RFT, PT/INR, APTT, FLP, FBS, PPBS, Fasting Insulin,CRP, GGT, gut flora, fatigue score, global health score Timepoint: Day 0, Day 90 and Day180	—

Secondary

Measure	Time frame
Inflammatory markers, International Physical Activity Questionnaire (IPAQ), Anthropometry, Global health scale ,Self-assessment of overall health., General Questionnaire , basic socio-demographic characteristics Timepoint: Day 0, Day 90 and Day180	—

Countries

India

Contacts

Public ContactDeepa MS

Government Ayurveda College

drdeepamadhavank@gmail.com8304874165

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026